These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 9432289

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
    Youdim MB, Weinstock M.
    Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
    [Abstract] [Full Text] [Related]

  • 3. Elucidating the mechanism of action and potential interactions of MAO-B inhibitors.
    Bainbridge JL, Page RL, Ruscin JM.
    Neurol Clin; 2008 Aug; 26(3 Suppl):S85-96, vi. PubMed ID: 18774444
    [Abstract] [Full Text] [Related]

  • 4. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR.
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [Abstract] [Full Text] [Related]

  • 5. Selective inhibitors of monoamine oxidase type B and the "cheese effect".
    Finberg JP, Gillman K.
    Int Rev Neurobiol; 2011 Dec; 100():169-90. PubMed ID: 21971008
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide.
    Nair NP, Ahmed SK, Kin NM.
    J Psychiatry Neurosci; 1993 Nov; 18(5):214-25. PubMed ID: 7905288
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Studies of selective and reversible monoamine oxidase inhibitors.
    Mann JJ, Aarons SF, Frances AJ, Brown RD.
    J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):62-6. PubMed ID: 6429130
    [Abstract] [Full Text] [Related]

  • 12. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
    Youdim MB, Fridkin M, Zheng H.
    Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. (-)-Trans-epsilon-viniferin, a polyphenol present in wines, is an inhibitor of noradrenaline and 5-hydroxytryptamine uptake and of monoamine oxidase activity.
    Yáñez M, Fraiz N, Cano E, Orallo F.
    Eur J Pharmacol; 2006 Aug 07; 542(1-3):54-60. PubMed ID: 16828740
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of monoamine oxidase by indole and benzofuran derivatives.
    Prins LH, Petzer JP, Malan SF.
    Eur J Med Chem; 2010 Oct 07; 45(10):4458-66. PubMed ID: 20674099
    [Abstract] [Full Text] [Related]

  • 16. Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease?
    Tabakman R, Lecht S, Lazarovici P.
    Bioessays; 2004 Jan 07; 26(1):80-90. PubMed ID: 14696044
    [Abstract] [Full Text] [Related]

  • 17. Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release.
    Finberg JP.
    Pharmacol Ther; 2014 Aug 07; 143(2):133-52. PubMed ID: 24607445
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy.
    Löscher W, Lehmann H, Teschendorf HJ, Traut M, Gross G.
    J Pharmacol Exp Ther; 1999 Mar 07; 288(3):984-92. PubMed ID: 10027835
    [Abstract] [Full Text] [Related]

  • 19. MDL 72,974A: a selective MAO-B inhibitor with potential for treatment of Parkinson's disease.
    Palfreyman MG, McDonald IA, Zreika M, Cremer G, Haegele KD, Bey P.
    J Neural Transm Suppl; 1993 Mar 07; 40():101-11. PubMed ID: 8294896
    [Abstract] [Full Text] [Related]

  • 20. Clinical pharmacology of MAO inhibitors: safety and future.
    Yamada M, Yasuhara H.
    Neurotoxicology; 2004 Jan 07; 25(1-2):215-21. PubMed ID: 14697896
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.